Babalola 2021: A Randomized Controlled Trial of Ivermectin Monotherapy versus Hydroxychloroquine, Ivermectin, and Azithromycin Combination Therapy in Covid-19 Patients in Nigeria

Research Square, Preprints
DOI: 10.21203/

The intent of this study was to compare treating Covid-19 with Ivermectin alone, or with a combination of Ivermectin, Hydroxychloroquine, and Azithromycin (HIA therapy).

In addition, both groups received “standard of care” treatment which included Zinc and Vitamin C, as well as Oxygen when needed.

Sixty patients requiring hospital treatment were randomized such that 30 patients were in each group.   None of them had been vaccinated.

It was found that both treatments resulted in recovery.  In both groups, all inflammatory markers relative to baseline dropped significantly by Day 7.   In both groups, there was a significant drop in white blood cell count by Day 7.   In both groups, patients made steady progress in wellness, reporting feeling “much better” by Day 7.

63% of the Ivermectin-only group were able to be discharged from the hospital by Day 7, while only 44% of the combination (HIA) group were ready for discharge.  The difference, however, was not significant

The authors conclude that ivermectin alone does such a good job that there is little room for improvement by adding the other medications, which work in a similar way.

Figure 10:  Self-reported clinical status of patients over time using adjusted predictions of treatment-by-day interaction with 95% confidence interval error bars. 1-much worse/very bad;  5-Much improved/very good.

MedLine || Full Text

This entry was posted in 2021-2025, COVID-19, HCQ, Ivermectin. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *